Antihypertensive medications and cancer risk: Evidence from 0.27 million patients with newly diagnosed hypertension
Despite previous controversy, in this study, we found no clinically meaningful cancer risk associated with antihypertensive medications. However, the association of CCBs with specific cancer still requires further research. These findings should be interpreted with caution due to the potential residual confounding.
Authors
- Heping Wang (ORCID: https://orcid.org/0000-0002-0153-478X)
- Yonghua Hu (ORCID: https://orcid.org/0000-0002-7255-8914)
- Kexin Ding (ORCID: https://orcid.org/0000-0002-6206-4398)
- Huan Yu
- Yiqun Wu (ORCID: https://orcid.org/0000-0002-5554-1678)
- Liyang Zheng (ORCID: https://orcid.org/0000-0001-9960-3466)
- Siyan Zhan (ORCID: https://orcid.org/0000-0001-7252-5349)
- Jingxian Wu (ORCID: https://orcid.org/0000-0003-1167-6930)
- Kun Wang (ORCID: https://orcid.org/0000-0002-2522-2182)
- Hongbo Lin (ORCID: https://orcid.org/0000-0002-9953-4752)
- Peng Shen (ORCID: https://orcid.org/0000-0002-0176-127X)
- Zhike Liu (ORCID: https://orcid.org/0000-0002-3232-8196)
- Huziwei Zhou
- Feng Sun (ORCID: https://orcid.org/0000-0002-7052-6265)
- Ruotong Yang
Institutions
- Peking University (CN)
- Ningbo Center for Disease Control and Prevention (CN)
- Beijing Academy of Artificial Intelligence (CN)
- Peking University Third Hospital (CN)
- McGill University (CA)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.3389/fphar.2025.1559604
- Citations
- 2
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 2.94